Large-scale isotope supply capacity: We have independent intellectual property rights of isotope research and development and production technology.

Understand the needs of nuclear medicine enterprises and the requirements of regulatory authorities: obtained 2 approval numbers for drug delivery production (Note: Since 2013, China's drug regulatory authorities have only approved 8 kinds of radioactive drugs).

Business model: familiar with the international medical isotope and drug delivery operation model, and successful practice. It is the first time to put forward the concept of isotope localization in China, and has established a system and channel to adapt to China's drug sales, so that the market share of iodine products has increased from 0 to 20%. (Data source: Planning documents of eight ministries and commissions).